FDA approves Retatrutide this year?

This market asks whether the FDA will approve retatrutide, Eli Lilly's experimental drug for obesity, diabetes, and other conditions, by the end of 2026. The market resolves YES if the FDA issues a formal approval letter for any retatrutide-based product for any indication, including standard approval, accelerated approval, or approval with restrictions. Tentative approvals and approvable letters that require further action do not count. This tracks a significant moment in the development of a major pharmaceutical treatment.

Trade "FDA approves Retatrutide this year?" on PremiumBlock - a decentralized, on-chain prediction market. The market currently prices YES at about 12%. Settle in USDC with wallet sign-in and no KYC.